Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) shares shot up 15.3% during mid-day trading on Monday . The stock traded as high as $1.68 and last traded at $1.58. 866,786 shares were traded during trading, an increase of 82% from the average session volume of 477,068 shares. The stock had previously closed at $1.37.
Tiziana Life Sciences Price Performance
The business's 50 day moving average is $1.22 and its 200 day moving average is $1.03.
Institutional Investors Weigh In On Tiziana Life Sciences
Institutional investors and hedge funds have recently made changes to their positions in the stock. Dauntless Investment Group LLC purchased a new position in Tiziana Life Sciences in the 1st quarter worth $1,879,000. Jane Street Group LLC raised its stake in shares of Tiziana Life Sciences by 968.2% in the first quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock worth $181,000 after purchasing an additional 151,858 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in shares of Tiziana Life Sciences during the first quarter worth about $156,000. Bison Wealth LLC acquired a new position in Tiziana Life Sciences in the 4th quarter worth approximately $30,000. Finally, Geode Capital Management LLC increased its holdings in Tiziana Life Sciences by 12.4% in the 4th quarter. Geode Capital Management LLC now owns 245,722 shares of the company's stock worth $171,000 after buying an additional 27,041 shares during the period.
About Tiziana Life Sciences
(
Get Free Report)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Read More
Before you consider Tiziana Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.
While Tiziana Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
